West Virginia’s share of the bankruptcy settlement with pharmaceutical giant Purdue Pharma will probably be less than hoped. Attorneys say it’s become clearer that the settlement will be based on population, rather than the severity of the impact of OxyContin. More than three-thousand plaintiffs voted against using population to determine settlement amounts